Boris Pasche, President and CEO at Karmanos Cancer Institute, Chair Department of Oncology at Wayne State University, shared a post on LinkedIn:
“Congratulations to Suresh Balasubramanian for his outstanding contributions in the lab and as the Karmanos Principal Investigator for three pivotal studies (Phase I, Phase II, and Phase III) that culminated in the FDA approval of ziftomenib, branded as Komzifti, on November 13, 2025.
This achievement underscores the dedication to advancing therapies at the Karmanos Eisenberg Center for Experimental Therapeutics, where innovative research is transformed into FDA-approved treatments that significantly impact clinical practice.
Since 2020, 52 new therapies offered in clinical trials at Karmanos have received FDA approval, showcasing the center’s commitment to improving patient outcomes.
Karmanos Physician-Scientist Led Clinical Trial Studies, Preceding FDA-Approval of New Targeted Inhibitor for AML Patients | Karmanos News.”
More posts featuring Boris Pasche.